



CHEPLAPHARM ACQUIRES RIGHTS TO RIVOTRIL®

Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.

"As a successful start to the new year, we were able to complete this very important project for CHEPLAPHARM, which perfectly complements our portfolio of globally marketed benzodiazepines. We are proud to build on a long-standing relationship with Roche," says CEO Sebastian F. Braun, "and are pleased with the acquisition of the established brand among patients and prescribers."

Rivotril® is a branded prescription drug which is commonly used and indicated in the therapeutic area of epilepsy and panic disorder. This benzodiazepine with the active ingredient clonazepam is a well-established, globally marketed product. Rivotril® was launched in 1973 and is currently registered in approximately 85 countries.

About CHEPLAPHARM

CHEPLAPHARM is a pharmaceutical company headquartered in Greifswald, Germany, offering branded and niche products in more than 120 countries worldwide. The family-owned company specializes in selected active substances and indications and focuses on an international buy-and-build strategy. Working closely with its business partners, CHEPLAPHARM achieves sustainable annual growth rates. CHEPLAPHARM has been one of the fastest-growing pharmaceutical companies in Europe.

Please refer to www.cheplapharm.com for additional information.

Press office:

CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | [presse\(at\)cheplapharm.com](mailto:presse(at)cheplapharm.com)